Tweets
#Scleroderma updated #EULAR2024
#recommendations @eular_org
SKIN
Are they good enough?
Great work by task force @EUSTAR_org
Do we alter initial Rx if v high mRSS?
Ex #MMF not much improvement on skin vs #RTX #Cyclo
Or combo Rx?
We need to improve #SoC
?CAR-T ? RCT
@RheumNow https://t.co/WhEzDdjVeu
Janet Pope @Janetbirdope ( View Tweet )
1 year 7 months ago
#Scleroderma updated #EULAR2024
#recommendations @eular_org
Are they good enough?
Great work by task force @EUSTAR_org
#PAH my thoughts
Where does #sotaracept in #PAH fit in
Not mentioned
?#selexipag before #epoprostenol
For sure there is country variant
@RheumNow https://t.co/3dJ6eusSkU
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 year 7 months ago
#EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
LBA0001 UPA in GCA- Phase 2 RCT
15mg UPA with 26w steroid taper showed
⬆️ efficacy
⬇️ steroid use
vs placebo with 52w steroid taper
Potential new target on the horizon for #GCA??
@RheumNow #EULAR2024
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 7 months ago
#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s.
This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too
ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr
Links:
David Liew @drdavidliew ( View Tweet )
1 year 7 months ago
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
Points to consider in pregnancy &lactation in Pts w #rheumatic #diseases
#biologics don’t increase rate of serious infections in
Mom
Baby
Compared to other matched pregnant and post partum women
reassuring!
#EULAR2024
@RheumNow @eular_org
Janet Pope @Janetbirdope ( View Tweet )
1 year 7 months ago
What to use in men prior to planned conception of partner in
#rheumatic #diseases
#EULAR2024 @RheumNow @ACRheum @eular_org https://t.co/jMecV8jqUe
Janet Pope @Janetbirdope ( View Tweet )
1 year 7 months ago
MINIMAL SPINAL RADIOGRAPHIC PROGRESSION in RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY - 90% nonprogressers on Bime including how many would never have progressed ? @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
Points to consider in pregnancy in
#rheumatic diseases
3 points
✅TNFi all OK 👍
? Only if you can’t control disease use other #bDMARDs
Baby #vaccinations if exposed to #biologics while present
#rotovirus ok
other live vaccines >6 mos
#EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 year 7 months ago
POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA
Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i
@SteZhao @RheumNow #EULAR2024
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 7 months ago
